Literature DB >> 3003197

A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells.

J Chassagne, P Verrelle, C Dionet, F Clavel, F Barre-Sinoussi, J C Chermann, L Montagnier, J C Gluckman, D Klatzmann.   

Abstract

A murine monoclonal antibody (MAb), named C.V.K., was produced after immunization with highly purified and sonicated lymphadenopathy-associated virus (LAV). No monoclonal antibody was observed with intact virus used as immunogen. C.V.K. MAb recognizes an epitope present on the precursor gag protein of 55 kilodaltons. Western blot analysis and pulse-chase experiments support the interpretation that after p55 cleavage into p25, p18, and p13, only p18 expresses this epitope. C.V.K. MAb selectively stained only LAV-infected lymphocytes. This intracytoplasmic staining appears 3 days after the infection and is correlated with reverse transcriptase activity. Neither membrane immunofluorescence of infected lymphocytes nor neutralizing activity was observed with C.V.K. MAb. These facts suggest that p55 and p18 are not expressed at the cell membrane or on the viral envelope. C.V.K. MAb should prove useful not only in the purification of core proteins but also for detecting infected cells producing the virus in suspension or on histologic sections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

2.  Cell surface expression of several species of human immunodeficiency virus type 1 major core protein.

Authors:  A G Laurent; B Krust; M A Rey; L Montagnier; A G Hovanessian
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Characterization of monoclonal antibodies directed against distinct conserved epitopes of human immunodeficiency virus type 1 core proteins.

Authors:  M Tatsumi; C Devaux; F Kourilsky; J C Chermann
Journal:  Mol Cell Biochem       Date:  1990-08-10       Impact factor: 3.396

5.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus.

Authors:  B D Jamieson; J A Zack
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Persistent diarrhoea in Zairian AIDS patients: an endoscopic and histological study.

Authors:  R Colebunders; K Lusakumuni; A M Nelson; P Gigase; I Lebughe; E van Marck; B Kapita; H Francis; J J Salaun; T C Quinn
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

8.  Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level.

Authors:  L Pedroza-Martins; K B Gurney; B E Torbett; C H Uittenbogaart
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

9.  Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.

Authors:  Vanessa B Soros; Wes Yonemoto; Warner C Greene
Journal:  PLoS Pathog       Date:  2007-02       Impact factor: 6.823

10.  Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene.

Authors:  Janet Chung; Lisa J Scherer; Angel Gu; Agnes M Gardner; Monica Torres-Coronado; Elizabeth W Epps; David L Digiusto; John J Rossi
Journal:  Mol Ther       Date:  2014-02-28       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.